1. Introduction {#sec1}
===============

Familial aniridia is a congenital disease caused by autosomal dominant mutations in the *PAX6* gene that disrupt the development and function of almost all eye structures \[[@B1], [@B2]\]. While aniridia is named for iris hypoplasia, a feature of the trait that is often readily evident without a specialized examination, the main causes of early visual impairment are optic nerve and foveal hypoplasia. Further, many affected individuals suffer progressive vision loss due to glaucoma or limbal stem cell deficiency. The severity of visual impairment and phenotypic expression in affected individuals varies \[[@B3]--[@B5]\].

The *PAX6* gene, located on chromosome 11p13, encodes a transcription factor that is vital for ocular development \[[@B6], [@B7]\]. *PAX6* is expressed in the surface ectoderm and neural ectoderm during early eye development and is essential for the specification and differentiation of the cornea, lens, ciliary body, retina, and optic nerve \[[@B8]--[@B16]\]. To date, 221 mutations in *PAX6* have been reported; most are associated with aniridia, though some mutations are associated with other ocular diseases such as coloboma, morning glory disc anomaly, anterior segment dysgenesis, and cataract with late-onset corneal dystrophy (ClinVar: PAX6\[gene\]) \[[@B2]--[@B6], [@B17]--[@B37]\]. Due to its gene-dosage effect, decreased protein function or expression of a single copy of *PAX6* results in characteristic ocular malformations \[[@B11], [@B17], [@B20], [@B38]\]. While aniridia can be sporadic, the mode of inheritance for the familial form is considered autosomal dominant; however, unlike classical autosomal dominance, PAX6 inheritance shows two phenotypes associated with the different genotypic combinations. Specifically, the presence of one defective copy of PAX6 results in ocular malformations, but mutations in both copies of *PAX6* cause ocular phenotypes that are more severe (e.g., anophthalmia) and brain abnormalities that are incompatible with life \[[@B6], [@B39], [@B40]\]. Differences in expressivity are seen when comparing one *PAX6* mutation to another. However, studies have reported that even within families carrying the same mutation, individuals may have different ocular findings \[[@B3], [@B5], [@B24], [@B35]\]. In the current study, we describe the relationships and detailed phenotypes in a 4-generation family in which individuals affected with aniridia carry a novel loss-of-function *PAX6* frameshift mutation. Our findings confirm that significant intrafamily phenotypic variability occurs among individuals carrying the same *PAX6* mutation.

2. Methods {#sec2}
==========

This study was approved by the University of Michigan Institutional Review Board and complied with the US Health Insurance Portability and Accountability Act of 1996 and the Declaration of Helsinki. Informed consent was obtained either from participating individuals or from parents of minor patients. A retrospective chart review was performed on a family that had four generations of individuals affected by aniridia. The following data were collected: age, sex, ocular diagnoses, and history of intraocular surgeries. Visual acuities, anterior segment and fundus examinations, intraocular pressures (IOP), refraction, strabismus examination, and ocular medications were recorded from the last examination. Visual acuity was determined by Snellen or Allen figure optotypes in adults and verbal children. Teller visual acuity cards with conversion to Snellen equivalent were used in preverbal children. Anterior and posterior segment exams were performed using slit lamp biomicroscopy and indirect ophthalmoscopy. IOPs were obtained by Goldmann applanation, Tono-Pen (Reichert, Depew, NY, USA) or iCare (Revenio, Vantaa, Finland) tonometry.

2.1. PAX6 Mutation Screening {#sec2.1}
----------------------------

Genomic DNA was extracted from buccal epithelial cells obtained by swabs or mouthwash samples of the recruited individuals using the DNeasy kit (Qiagen, Hilden, Germany). Eleven exons of the *PAX6* coding region were amplified from genomic DNA by polymerase chain reaction (PCR) using AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA). PCR primers and conditions are listed in [Table 1](#tab1){ref-type="table"}. PCR cycling conditions were as follows: denaturation at 94°C for 10 minutes then amplification with 36 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 1 minute, with a final extension at 72°C for 10 minutes. PCR products were verified by the size of amplicons on a 1% agarose gel electrophoresis, diluted, and sequenced via Sanger dideoxynucleotide partial chain termination sequencing on an ABI3730 DNA Analyzer (Applied Biosystems) at the University of Michigan DNA Sequencing Core. All exons were sequenced with the same primers used for amplification, except exon 8 for which the following primer was additionally used: 5′- AGGCTGTCGGGATATAATGC-3′. All variants were compared to high-quality sequence reads in the Exome Aggregation Consortium (ExAC) database. Segregation was confirmed by screening DNA from all available affected and unaffected individuals in the family.

3. Results {#sec3}
==========

Seven related patients affected with familial aniridia were identified and recruited for this study. There were 3 female and 4 male patients and the ages ranged from 2 to 31 years. Based on information obtained by family history, a 4-generation pedigree was constructed, which included a total of 13 affected individuals ([Figure 1](#fig1){ref-type="fig"}). The clinical findings for the 7 patients in which genetic analysis was performed are described in [Table 2](#tab2){ref-type="table"}.

3.1. Patient III-5 {#sec3.1}
------------------

Patient III-5 is a 29-year-old male with no previous history of glaucoma or ocular surgeries. He has no history of diabetes or other metabolic abnormalities. At the time of his last examination, his best-corrected visual acuity was 20/150 in each eye individually and 20/100 binocularly. IOPs were 23 mmHg in the right eye and 19 mmHg in the left eye. Slit lamp biomicroscopy of both eyes showed mild corneal pannuses, hypoplastic irides with small remnant stumps, and visually insignificant cortical cataracts. Funduscopic examination revealed bilateral foveal hypoplasia and optic nerve hypoplasia. The cup to disc ratio in the right eye was 0.1 and in the left eye was 0.3. The patient had bilateral small amplitude and high-velocity horizontal nystagmus with no relative null point, and he was orthophoric.

3.2. Patient IV-1 {#sec3.2}
-----------------

Patient IV-1 is the 3-year-old son of patient III-5. He has a body mass index of 23.7 kg/m^2^ and to date has no history of diabetes or other metabolic problems. Unlike his father, he was diagnosed with glaucoma at 4 months of age and underwent placement of a Baerveldt101-350 glaucoma drainage device (Abbott Medical Optics, Santa Ana, CA, USA) in his left eye at 6 months of age and in his right eye at 9 months of age. He also underwent bilateral medial rectus recessions for esotropia at 2 years of age. At his last examination, his best-corrected visual acuity was 20/200 in each eye and binocularly. The patient was not on any glaucoma medications, and IOPs were 13 mmHg in the right eye and 14 mmHg in the left eye. Slit lamp examination of each eye showed a superotemporal glaucoma drainage device with an overlying bleb. The tube in each eye was oriented vertically along the temporal zonules and was not touching the cornea or lens. The corneas were clear with minimal pannuses, the irides were hypoplastic with small remnant stumps, and the lenses were clear. Fundoscopic examination showed foveal and optic nerve hypoplasia. The optic nerves had a cup to disc ratio of 0.0 in each eye. Cycloplegic refraction was +1.00 + 1.00 × 90 in the right eye and + 1.00 + 1.00 × 80 in the left eye. Like his father, the patient had bilateral small amplitude and high-velocity horizontal nystagmus with no relative null point, and he was orthophoric in all gazes.

3.3. Patient III-8 {#sec3.3}
------------------

Patient III-8 is a 31-year-old woman who is a first cousin of patient III-5. She has a history of type 1 diabetes mellitus that was diagnosed at 5 years of age and has been on an insulin pump since 2009. Her last hemoglobin A1C was 7.7% and her current body mass index was 47.8 kg/m^2^. She also has a history of hypothyroidism, which is well-controlled on levothyroxine. She underwent cataract extraction with intraocular lens placement in both eyes when she was 15 years old. At 20 years of age, she was diagnosed with glaucoma, which has been managed medically with use of timolol and dorzolamide. She also has a history of a V-pattern exotropia for which she underwent bilateral lateral rectus recessions at 2 years of age and bilateral medial rectus resections and bilateral inferior oblique recessions at 2.5 years of age. She then developed a consecutive esotropia and underwent bilateral medial rectus recessions with inferior transpositions and left inferior oblique anteriorization at 7 years of age. At her last examination, her best-corrected visual acuity was 20/125 in the right eye and 20/200 in the left eye and her IOPs by Goldmann applanation were 14 mmHg in the right eye and 17 mmHg in the left eye. Slit lamp examination showed corneal epithelial irregularities and pannus with neovascularization in both eyes (arrows, [Figure 2(a)](#fig2){ref-type="fig"}). The irides were hypoplastic with small remnant stumps (arrowheads, [Figure 2(a)](#fig2){ref-type="fig"}). Fundoscopic examination showed foveal hypoplasia. The optic nerves were hypoplastic and had a cup to disc ratio of 0.4 in the right eye and 0.5 in the left eye. Refraction was −2.25 + 4.00 × 160 in the right eye and − 1.50 + 2.50 × 85 in the left eye. She had horizontal high-velocity nystagmus of both eyes and a V-pattern exotropia. Per patient and family report, both of her parents had aniridia (II-4 and II-5).

3.4. Patient IV-4 {#sec3.4}
-----------------

Patient IV-4 is the 10-year-old son of patient III-8 and second cousin of patient IV-1. His last body mass index was 23.8 kg/m^2^ and to date has no history of diabetes or other metabolic abnormalities. He was diagnosed with glaucoma at 5 years of age and underwent placement of Baerveldt 101-350 glaucoma drainage devices in both eyes at 6 years of age. He also has a history of a V-pattern esotropia and bilateral medial rectus recessions with half tendon infraplacement. Further, bilateral inferior oblique partial anteriorization was performed at 3 years of age. At his last examination, his best-corrected visual acuity was 20/300 in the right eye, 20/250 in the left eye, and 20/200 binocularly. IOPs were 14 mmHg in the right eye and 17 mmHg in the left eye on timolol and dorzolamide in both eyes. Slit lamp examination showed superotemporal glaucoma drainage devices with overlying blebs. The tubes were in the anterior chamber, oriented vertically along the temporal zonules without corneal or lens touch. Both corneas had 360 degrees of pannus with neovascularization (arrows, [Figure 2(b)](#fig2){ref-type="fig"}). In the right eye, the pannus extended into the visual axis and had underlying corneal stromal haze. The irides were hypoplastic with short remnant stumps (arrowheads, [Figure 2(b)](#fig2){ref-type="fig"}). There were mild cortical and posterior subcapsular cataracts that were not visually significant. Fundoscopic examination showed optic nerve and foveal hypoplasia. The optic nerves had a cup to disc ratio of 0.8 and 0.6 for the right and left eye, respectively. Cycloplegic refraction was −3.50 in the right eye and −3.00 in the left eye. He had bilateral moderate amplitude and moderate velocity horizontal nystagmus with no null point, and he showed a 50 prism diopter exotropia.

3.5. Patient IV-5 {#sec3.5}
-----------------

Patient IV-5 is the 3-year-old son of patient III-8, brother of patient IV-4, and second cousin of patient IV-1. He has no history of diabetes or metabolic abnormalities. He was diagnosed with glaucoma at 2 years of age and has been medically managed with timolol and dorzolamide in both eyes. At his last examination, visual acuity by Teller Acuity cards was estimated to be 20/380 in each eye individually and 20/260 binocularly. IOPs were 20 mmHg in the right eye and 15 mmHg in the left eye. Slit lamp examination showed clear corneas without pannuses, and hypoplastic irides were very small remnant stumps. There was a focal cortical cataract in the right eye that was not visually significant. Fundoscopic examination showed foveal hypoplasia in both eyes. The optic nerves had no cupping or evidence of hypoplasia. The patient has a small amplitude, has high-velocity horizontal nystagmus with a null point in left gaze, and has a 45 prism diopter exotropia. His cycloplegic refraction was −3.50 + 2.00 × 120 in the right eye and −3.50 + 2.00 × 60 in the left eye.

3.6. Patient III-11 {#sec3.6}
-------------------

Patient III-11 is a 29-year-old male who is first cousins with patient III-4 and patient III-8. He has no history of diabetes or metabolic abnormalities. His ocular history is notable for bilateral Peters anomaly and partial iris hypoplasia ([Figure 2(c)](#fig2){ref-type="fig"}). At 2 months of age, he underwent penetrating keratoplasty of the right eye, which subsequently became vascularized and was not replaced due to poor visual potential. In the left eye, he underwent extracapsular cataract extraction at 2 years of age. He developed glaucoma of the left eye, which necessitated 2 trabeculectomies with mitomycin C at 6 years of age and 2 treatments of cyclophotocoagulation at 7 years of age. The left cornea underwent a superficial keratectomy for band keratopathy at 9 years of age and then penetrating keratoplasty at 11 years of age. The left corneal graft was complicated by persistent epithelial defects and by 20 years of age, the graft had failed and the patient did not desire repeat penetrating keratoplasty. At his last examination, he was not able to see the 20/800 optotypes and was only able to detect the number of fingers held at 1 foot in front of each eye. IOPs were 20 mmHg in the right eye and 15 mmHg in the left eye on timolol. Slit lamp examination on the right showed a corneal graft with central and inferior conjunctivalization, hypoplastic iris, and white cataract. The left eye had a corneal graft with diffuse stromal thickening, band keratopathy, and 360 degrees of pannus and hypoplastic iris. Neither eye had a view to the fundus.

3.7. Patient IV-6 {#sec3.7}
-----------------

Patient IV-6 is a 5-year-old daughter of patient III-11 and second cousin to patients IV-1, IV-4, and IV-5 and has no history of diabetes or metabolic abnormalities. Further, she has no history of glaucoma or previous ocular surgeries. At her last examination, her best-corrected visual acuity was 20/150 in the right eye and 20/100 in the left eye. She was unable to tolerate IOP testing, but both eyes were soft by digital palpation. Slit lamp examination of both eyes showed mild corneal pannuses, small remnant iris stumps, and trace visually insignificant posterior subcapsular cataracts. Fundoscopic examination showed foveal hypoplasia and normal optic nerves with cup to disc ratios of 0.2 in both eyes. Cycloplegic refraction was +0.2 5 + 4.25 × 102 in the right eye and + 1.25 + 5.00 × 70 in the left eye. She had a 9 prism diopter esotropia and horizontal nystagmus of both eyes.

3.8. *PAX6* Mutational Analysis {#sec3.8}
-------------------------------

The paired homeobox gene PAX6 gene on chromosome 11p13 comprises two major splice forms, with a total of 14 exons, including 11 coding exons. *PAX6* gene sequencing was performed on all seven patients in this study, and three unaffected family members A novel frameshift mutation from a single nucleotide deletion (NM_000280.4(PAX6):c.565TC\>T) was found to perfectly segregate in all seven patients with aniridia and was absent in family members without aniridia ([Figure 3](#fig3){ref-type="fig"}). Individual III-8 was found to carry a single *PAX6* mutation presumably inherited from her mother, despite the reported history that both of her parents had aniridia. This frameshift mutation p.Ile190SerfsTer17 in exon 8 of *PAX6* is predicted to cause an early stop codon and a functionally null *PAX6* allele. This mutation was not found in the ClinVar or ExAC databases.

4. Discussion {#sec4}
=============

The ocular phenotypes associated with *PAX6* mutations underscore the essential role of *PAX6* in eye development. The "classic" presentation of aniridia includes iris, optic nerve, and foveal hypoplasia and congenital cataracts with progressive corneal opacification due to limbal stem cell deficiency \[[@B1], [@B20], [@B41]\]. In addition, approximately 50% of affected individuals have glaucoma secondary to anterior rotation of the iris root and/or inherent goniotrabeculodysgenesis \[[@B26], [@B32], [@B38], [@B42], [@B43]\]. However, there is a phenotypic spectrum associated with *PAX6* mutations, which can include some to all of the abovementioned ophthalmic findings as well as congenital corneal opacification (Peters anomaly), anterior segment dysgenesis, and colobomas \[[@B4], [@B6], [@B17], [@B20], [@B25], [@B32], [@B34]\].

PAX6 is a transcription factor, which has 2 DNA-binding domains, a long paired domain, and a homeodomain \[[@B44]\]. Disease-causing mutations span the *PAX6* coding sequence and regulatory regions. Missense mutations are associated with milder phenotypes such as isolated congenital cataracts, anterior segment dysgenesis, and colobomas \[[@B2], [@B6], [@B27], [@B32], [@B34], [@B45]\]. In contrast, large deletions and mutations that cause premature stop codons are associated with aniridia. We identified a novel frameshift mutation (NM_000280.4(PAX6):c.565TC\>T) from a single nucleotide deletion in exon 8, which encodes the initial homeodomain sequence. It is hypothesized that truncated mutant *PAX6* mRNA is degraded through nonsense-mediated decay prior to translation \[[@B42], [@B43]\]. Thus, it is predicted to be a complete loss of a function *PAX6* allele, consistent with the aniridia phenotype.

In the current study, we present an example of phenotypic variation in a 4-generation family with aniridia. Of the 7 affected individuals who were genotyped, the visual acuity ranged from 20/100 to worse than 20/800. Within our family, all affected individuals had foveal hypoplasia, which is the main cause of visual impairment. Six of the 7 individuals had almost complete iris hypoplasia. Two individuals had progressive corneal irregularities with significant pannus and corneal neovascularization, due to severe limbal stem cell deficiency. Five individuals were diagnosed with glaucoma between 4 months and 20 years of age, and 3 required surgery to obtain IOP control. Most notably, one individual had bilateral congenital corneal opacifications (Peters anomaly), which resulted in poor vision after failed corneal transplantation in both eyes. These results indicate that the same *PAX6* mutation can yield a wide range of ocular phenotypes and that more severe visual impairment correlated with glaucoma and corneal opacification, requiring surgical intervention.

The phenotypic variation associated with *PAX6* mutations may be due to differences in genetic background that affect the expression of *PAX6* coregulators and downstream targets. *PAX6* encodes a transcription factor that is an early marker of neural epithelium and demarcates specific domains of the developing central nervous system. Within the neural epithelial-derived optic vesicle, animal studies have demonstrated that *Pax6* acts together with additional transcription factors such as *Pax2*, *Six6*, *Gsx2*, *Pax5*, and *Lhx2* to regulate invagination to form the bilayered cup that will become the retina, retinal pigmented epithelium, and iris pigmented epithelium \[[@B8], [@B10], [@B12], [@B46]\]. Further, *Pax6* is specifically expressed in the lens placode through a combination of activation by *Sox2*, *Oct-1*, and *Foxe3* in the surface ectoderm and inhibition by TGF*β* and Wnt signaling in the periocular neural crest \[[@B47]--[@B51]\]. Together, these signaling pathways stimulate separation of the lens vesicle from the overlying surface ectoderm and neural crest migration into the anterior segment. Minor alterations in expression or function of these additional signaling pathways and coregulators through single nucleotide polymorphism variants may exacerbate or mitigate the effect of a *PAX6* mutation during different processes of eye development.

Transcriptional and epigenetic regulation also alter the function of *PAX6*, which may result in different ocular phenotypes. The *PAX6* locus is complex and is regulated by three promoters. The P0 and P1 promoters drive expression of the *Pax6* transcript and the alternatively spliced *Pax6(5a)* variant, while the internal P*α* promotor encodes truncated Pax6 p32 proteins that lack the DNA-binding paired domain \[[@B52], [@B53]\]. The specific regulation of the P*α* promoter and the function of these truncated proteins have yet to be determined. In addition, the paired domain of *Pax6(5a)* has a different DNA-binding capacity, and this variant primarily plays a role in iris formation \[[@B54]\]. Stochastic events, which may differentially regulate the transcription and activity of *Pax6* and the *Pax6(5a)* variant, may influence phenotype. Further, epigenetic alteration of *PAX6* regulates DNA binding, transcriptional activation, and protein degradation. For example, posttranslational sumoylation of the Pax6 p32 protein by SUMO-1 enhances DNA-binding activity of the homeodomain and increases transcriptional activation of target proteins \[[@B55]\]. In contrast, Trim11, a ubiquitin E3 ligase decreases *PAX6* activity by tagging the protein for degradation by the proteasome \[[@B56]\]. In addition, the DNA-binding activity of the *PAX6* homeobox domain is modified by histone variants such as *H3K4me1*, *H3K27ac*, *H3K4m3*, and *H3K37me3* \[[@B57]\]. Thus, *PAX6* transcription and protein function are regulated at multiple levels, all of which are targets for differential expression and activity in the functional copy of PAX6. These may account for the phenotypic variability in the ocular findings associated with dominantly inherited *PAX6* null mutations.

In addition to its role in ocular development, *PAX6* has been shown to regulate pancreatic islet cell development \[[@B58], [@B59]\]. The clinical implications of *PAX6* mutations on glucose tolerance are unclear as published studies include few patients and show conflicting results \[[@B60], [@B61]\]. In our study, only 1 patient had a history of type 1 diabetes, while the remainder of the individuals had no history of glucose intolerance. Additional studies, which include a larger number of individuals with aniridia, are required to better understand whether *PAX6* mutations also have phenotypic variability in regards to glucose regulation.

In the current study, we describe a novel disease-causing frameshift mutation (NM_000280.4(PAX6):c.565TC\>T) in *PAX6* in a 4-generation family affected with aniridia. Family members with aniridia showed phenotypic variation and differences in visual outcomes that correlated with surgical intervention for glaucoma or corneal opacification. Further studies which investigate modifications and interactions of *PAX6* are required for better understanding of the phenotypic variations in aniridia.

5. Conclusions {#sec5}
==============

We describe a novel disease-causing frameshift mutation (NM_000280.4(PAX6):c.565TC \> T) in *PAX6* which showed phenotypic variation in a 4-generation family. Differences in ocular comorbidities resulted in a range of visual outcomes in affected individuals.
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![Four-generation family with familial aniridia. Pedigree of a four-generation family in which 13 individuals were affected with familial aniridia (gray circles and gray squares). The plus sign (+) denotes individuals who underwent *PAX6* sequencing and affected individuals with genetic confirmation of the novel frameshift mutation PAX6 p.Ile190SerfsTer17. The arrow indicates the proband. The star (^∗^) indicates a family member with reported aniridia.](JOPH2018-5978293.001){#fig1}

![Phenotypic variations in individuals with *PAX6* p.Ile190SerfsTer17. mutation. Anterior segment photographs of the right and left eyes of individuals with the *PAX6* NM_000280.4(PAX6):c.565TC\>T frameshift mutation showed phenotypic variation. Patient III-8 (a) at 31 years of age had almost complete iris hypoplasia with small remnant stumps (arrowheads), intraocular lenses, and corneal pannuses with neovascularization (arrows) in both eyes. In the left eye, the corneal pannus was associated with underlying stromal scarring. Patient IV-4 (b) at 5 years of age, prior to placement of glaucoma drainage devices, had corneal pannuses with neovascularization (arrows) and corneal epithelial irregularities in both eyes. Patient IV-4 also had almost complete iris hypoplasia with small remnant stumps (arrowheads) in both eyes. Patient III-11 (c) at 2 months of age, prior to penetrating keratoplasty, had bilateral central corneal opacities consistent with Peters anomaly (arrows) with the opacity of the right eye much denser than the left eye. However, patient III-11 exhibited only partial iris hypoplasia (arrowheads) in both eyes.](JOPH2018-5978293.002){#fig2}

![Sequencing confirming *PAX6* frameshift mutation. Schematic of *PAX6* gene shows the location of the NM_000280.4(PAX6):c.565TC\>T frameshift mutation and its effect on the coding protein. The Sanger chromatogram traces show transmission of the mutation from father (III-11) to daughter (IV-6) in one branch of the family and absence of the mutation in the unaffected mother (III-10).](JOPH2018-5978293.003){#fig3}

###### 

PCR primer sequences.

  Exon   Forward primer             Chromosomal coordinates^∗^    Reverse primer             Chromosomal coordinates^∗^    Fragment size
  ------ -------------------------- ----------------------------- -------------------------- ----------------------------- ---------------
  4      TTCCAGTACTTTGTTTCAAGCCCC   chr11:31,806,650-31,806,673   AAACTCGGGCGGGCTGTTCTTAAG   chr11:31,806,160-31,806,183   514 bp
  5      CCTCTTCACTCTGCTCTCTT       chr11:31,802,874-31,802,893   ATGAAGAGAGGGCGTTGAGA       chr11:31,802,637-31,802,656   258 bp
  5a     TGAAAGTATCATCATATTTGTAG    chr11:31,801,999-31,802,021   GGGAAGTGGACAGAAAACCA       chr11:31,801,785-31,801,804   237 bp
  6      TGAAAGTATCATCATATTTGTAG    chr11:31,801,999-31,802,021   AGGAGAGAGCATTGGGCTTA       chr11:31,801,507-31,801,526   515 bp
  7      CAGGAGACACTACCATTTGG       chr11:31,800,880-31,800,899   CAGGCCTTCAAATGCAGTCTCACC   chr11:31,800,557-31,800,580   343 bp
  8      GGGAATGTTTTGGTGAGGCT       chr11:31,794,891-31,794,910   CAAAGGGCCCTGGCTAAATT       chr11:31,794,540-31,794,559   371 bp
  9      GTAGTTCTGGCACAATATGG       chr11:31,794,136-31,794,155   GTACTCTGTACAAGCACCTC       chr11:31,793,950-31,793,969   206 bp
  10     GTAGACACAGTGCTAACCTG       chr11:31,793,820-31,793,839   CCCGGAGCAAACAGGTTTAA       chr11:31,793,597-31,793,616   243 bp
  11     TTAAACCTGTTTGCTCCGGG       chr11:31,793,597-31,793,616   AGTGCGAAAAGCTCTCAAGGGTGC   chr11:31,793,326-31,793,349   291 bp
  12     GCTGTGTGATGTGTTCCTCA       chr11:31,790,891-31,790,910   TTTCCCTTTTCAATCCCCATCCCC   chr11:31,790,566-31,790,589   345 bp
  13     CATGTCTGTTTCTCAAAGGGA      chr11:31,790,055-31,790,075   CCCCAGTGGTACAATACAGGACAC   chr11:31,789,782-31,789,805   294 bp

^∗^UCSC human genome, hg38 accessed 9/10/2017. In a 25 *μ*L PCR reaction for each coding exon, 0.3 *μ*L of AmpliTaq Gold (Applied Biosystems), with 2 *μ*L of 25 mM MgCl2, 0.2 of 25 mM dinucleotide triphosphate, and 0.5 *μ*L of 25 mM primers were used. For exon 4, we used 5 *μ*L of Q-solution (Qiagen) and changed MgCl2 volume to to 2.5 *μ*L and accounted for this from the water to keep the reaction volume at 25 *μ*L. In all of the amplicons, genomic DNA was denatured at 94°C for 10 minutes then amplified by 36 cycles of 94°C denaturation for 30 seconds, 60°C annealing for 30 seconds, and 72°C extension for 1 minute with final extension of 72°C for 10 minutes.

###### 

Summary of clinical findings.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   VA               Initial anterior segment findings                                       Initial posterior segment findings   IOP (mmHg) glaucoma meds   Glaucoma diagnosis (Dx) and glaucoma surgeries                               Other ocular surgeries
  --------- ---------------- ----------------------------------------------------------------------- ------------------------------------ -------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  III-5     OD: 20/150\      Corneal pannuses\                                                       Foveal hypoplasia\                   OD: 23\                    No glaucoma                                                                  OD: none\
            OS: 20/150\      Hypoplastic irides\                                                     Optic nerve Hypoplasia               OS: 19\                                                                                                 OS: none
            OU: 20/100       Cortical cataracts                                                                                           No meds                                                                                                 

  IV-1      OD: 20/200\      Corneal pannuses\                                                       Foveal hypoplasia\                   OD: 13\                    Glaucoma Dx @ 0.3 years\                                                     Strabismus: s/p bilateral medial rectus recessions
            OS: 20/200\      Hypoplastic irides                                                      Optic nerve Hypoplasia               OS: 14\                    OD: s/p Baerveldt 101-350\                                                   
            OU: 20/200                                                                                                                    No meds                    OS: s/p Baerveldt 101-350                                                    

  III-8     OD: 20/125\      Corneal epithelial irregularities and pannus with neovascularization\   Foveal hypoplasia\                   OD: 14\                    Glaucoma Dx @ 20 years\                                                      OD: s/p ECCE-IOL\
            OS: 20/200       Hypoplastic irides                                                      Optic Nerve hypoplasia               OS: 17\                    No glaucoma surgeries                                                        OS: s/p ECCE-IOL\
                                                                                                                                          Timolol\                                                                                                Strabismus: s/p bilateral lateral rectus Recessions, s/p Bilateral Inferior Oblique Recessions, s/p Bilateral Medial Rectus Recessions with Inferior Transpositions, s/p Left Inferior Oblique Anteriorization
                                                                                                                                          Dorzolamide                                                                                             

  IV-4      OD: 20/300\      Corneal pannus\                                                         Foveal hypoplasia\                   OD: 14\                    Glaucoma Dx @ 5 years\                                                       Strabismus: s/p bilateral medial rectus recessions with half tendon infraplacement, s/p bilateral inferior oblique partial anteriorization
            OS: 20/250\      Cortical and posterior subcapsular cataracts                            Optic nerve Hypoplasia               OS: 17\                    OD: s/p Baerveldt 101-350\                                                   
            OU: 20/200                                                                                                                    Timolol\                   OS: s/p Baerveldt 101-350                                                    
                                                                                                                                          Dorzolamide                                                                                             

  IV-5      OD: 20/380\      Hypoplastic irides\                                                     Foveal hypoplasia                    OD: 20\                    Glaucoma Dx @ 2 years\                                                       OD: none\
            OS: 20/380\      Focal cataract OD                                                                                            OS: 15\                    No glaucoma surgeries                                                        OS: none
            OU: 20/260                                                                                                                    Timolol\                                                                                                
                                                                                                                                          Dorzolamide                                                                                             

  III-11    OD: CF @ 1 ft\   Peters anomaly\                                                         Foveal hypoplasia                    OD: 20\                    Glaucoma Dx @ 6 years\                                                       OD: s/p penetrating keratoplasty\
            OS: CF @ 1 ft    Partial hypoplastic irides                                                                                   OS: 15\                    OD: none\                                                                    OS: s/p ECCE, s/p superficial keratectomy, s/p penetrating keratoplasty
                                                                                                                                          Timolol                    OS: s/p trabeculectomy with mitomycin C × 2, s/p cyclophotocoagulation × 2   

  IV-6      OD: 20/150\      Corneal pannuses\                                                       Foveal hypoplasia                    OD: unable\                No glaucoma                                                                  OD: none\
            OS: 20/100       Hypoplastic irides\                                                                                          OS: unable                                                                                              OS: none
                             Posterior subcapsular cataracts                                                                                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ECCE: extracapsular cataract extraction; IOL: intraocular lens; CF: counting fingers.
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